Avelumab ASCO news adds to alliance's 'momentous year,' say Merck KGaA and Pfizer

19 May 2017

German drugmaker Merck KGaA (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) have promised that 13 abstracts on avelumab across seven hard-to-treat cancers will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.

These will highlight the progress of avelumab as a monotherapy and potential novel combination treatment option, and of the alliance between the two companies, which signed a strategic alliance to co-develop and co-commercialize the drug in 2014.

Presentations will include data on avelumab in first-line metastatic merkel cell carcinoma (mMCC) and in previously treated metastatic urothelial carcinoma (UC), as well as results from the Phase Ib trial investigating avelumab in combination with the tyrosine kinase inhibitor axitinib, in advanced renal cell carcinoma (RCC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK